REGENERON PHARMACEUTICALS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
REGENERON PHARMACEUTICALS, INC. (REGN) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 of $0 for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-08.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 · last filed 2018-02-08
- REGENERON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2017-12-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2017-09-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2017-06-30 was $0.00.
- REGENERON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for the quarter ending 2017-03-31 was $0.00.
- REGENERON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2017 was $0.00.
- REGENERON PHARMACEUTICALS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers out of level 3 for fiscal 2016 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3 12 month |
|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $0.00 derived: sum of 2 quarters · filed 2018-02-08 | $0.00 derived: sum of 3 quarters · filed 2018-02-08 | $0.00 10-K · filed 2018-02-08 |
| 2017-09-30 | $0.00 10-Q · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | $0.00 derived: sum of 4 quarters · filed 2018-02-08 |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | $0.00 derived: sum of 3 quarters · filed 2018-02-08 | $0.00 derived: sum of 4 quarters · filed 2018-02-08 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 | $0.00 derived: sum of 2 quarters · filed 2018-02-08 | $0.00 derived: sum of 3 quarters · filed 2018-02-08 | $0.00 derived: sum of 4 quarters · filed 2018-02-08 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-08 | $0.00 derived: sum of 2 quarters · filed 2018-02-08 | $0.00 derived: sum of 3 quarters · filed 2018-02-08 | $0.00 10-K · filed 2018-02-08 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-08 | $0.00 derived: sum of 2 quarters · filed 2017-11-08 | $0.00 10-Q · filed 2017-11-08 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-03 | $0.00 10-Q · filed 2017-08-03 | ||
| 2016-03-31 | $0.00 10-Q · filed 2017-05-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |